Journal of Clinical Oncology, Vol 12, 1383-1389, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

B Camitta, D Mahoney, B Leventhal, SJ Lauer, JJ Shuster, S Adair, C Civin, L Munoz, P Steuber and D Strother
Department of Pediatrics, Medical College of Wisconsin, Milwaukee.

PURPOSE: To determine the potential efficacy and toxicity of intravenous (i.v.) methotrexate (MTX) and mercaptopurine (MP) as postremission intensification treatment for children with B-lineage acute lymphoblastic leukemia (ALL) at higher risk to relapse. PATIENTS AND METHODS: Eighty-three patients (age 1 to 20 years) with higher-risk B-lineage ALL were entered onto this protocol. Following standard four- drug remission induction, 80 patients received 12 intensive 2-week cycles of MTX/MP: MTX 200 mg/m2 i.v. push, then 800 mg/m2 i.v. 24-hour infusion on day 1; MP 200 mg/m2 i.v. in 20 minutes, then 800 mg/m2 i.v. 8-hour infusion day 2; MTX 20 mg/m2 intramuscularly day 8; and MP 50 mg/m2 by mouth days 8 to 14. Age-based triple intrathecal therapy (MTX, hydrocortisone, and cytarabine) was administered for CNS prophylaxis. Continuation therapy was weekly MTX/MP (as on days 8 to 14) for 2 years. RESULTS: Eighty-one patients (98%) entered remission. There were 28 relapses (marrow, n = 11; marrow and CNS, n = 2; isolated CNS, n = 9; testes, n = 5; ovaries, n = 1). No overt relapse occurred during the intensive phase of therapy. The event-free survival (EFS) rate at 4 years is 57.4% +/- 9.1% (SE). Hematologic, mucosal, and infectious toxicities were seen in 12%, 9%, and 5% of intensive MTX/MP courses, but were generally mild. CONCLUSION: Combined data from this and our previous trial suggest that intensive MTX/MP may produce long-term disease-free survival in 70 to 75% of children with B-lineage ALL. In comparison to other intensive regimens, intensive MTX/MP is easy to administer, effective, and relatively nontoxic. If patients at risk for failure of MTX/MP can be identified prospectively, more aggressive regimens could be restricted to this smaller (25% to 30%) cohort.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. R. Schultz, D. J. Pullen, H. N. Sather, J. J. Shuster, M. Devidas, M. J. Borowitz, A. J. Carroll, N. A. Heerema, J. E. Rubnitz, M. L. Loh, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Blood, February 1, 2007; 109(3): 926 - 935. [Abstract] [Full Text] [PDF]

				J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia Blood, June 15, 2005; 105(12): 4752 - 4758. [Abstract] [Full Text] [PDF]

				B. C. Bostrom, M. R. Sensel, H. N. Sather, P. S. Gaynon, M. K. La, K. Johnston, G. R. Erdmann, S. Gold, N. A. Heerema, R. J. Hutchinson, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood, May 15, 2003; 101(10): 3809 - 3817. [Abstract] [Full Text] [PDF]

				T. Dervieux, T. L. Brenner, Y. Y. Hon, Y. Zhou, M. L. Hancock, J. T. Sandlund, G. K. Rivera, R. C. Ribeiro, J. M. Boyett, C.-H. Pui, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo Blood, July 30, 2002; 100(4): 1240 - 1247. [Abstract] [Full Text] [PDF]

				L. B. Silverman, R. D. Gelber, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, M. A. Schorin, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Blood, March 1, 2001; 97(5): 1211 - 1218. [Abstract] [Full Text] [PDF]

				D. H. Mahoney Jr, J. J. Shuster, R. Nitschke, S. Lauer, C. P. Steuber, and B. Camitta Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 13, 2000; 18(6): 1285 - 1294. [Abstract] [Full Text] [PDF]

				B. H. Pollock, M. R. DeBaun, B. M. Camitta, J. J. Shuster, Y. Ravindranath, D. J. Pullen, V. J. Land, D. H. Mahoney Jr, S. J. Lauer, and S. B. Murphy Racial Differences in the Survival of Childhood B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., February 14, 2000; 18(4): 813 - 813. [Abstract] [Full Text] [PDF]

				C.-H. Pui, H. H. Mahmoud, G. K. Rivera, M. L. Hancock, J. T. Sandlund, F. G. Behm, D. R. Head, M. V. Relling, R. C. Ribeiro, J. E. Rubnitz, et al. Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia Blood, July 15, 1998; 92(2): 411 - 415. [Abstract] [Full Text] [PDF]

				J. B. Nachman, H. N. Sather, M. G. Sensel, M. E. Trigg, J. M. Cherlow, J. N. Lukens, L. Wolff, F. M. Uckun, and P. S. Gaynon Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy N. Engl. J. Med., June 4, 1998; 338(23): 1663 - 1671. [Abstract] [Full Text] [PDF]

				S. P. Hunger, M. Z. Fall, B. M. Camitta, A. J. Carroll, M. P. Link, S. J. Lauer, D. H. Mahoney, D. Jeanette Pullen, J. J. Shuster, C. Philip Steuber, et al. E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study Blood, February 1, 1998; 91(3): 1021 - 1028. [Abstract] [Full Text] [PDF]

				C.-H. Pui Childhood Leukemias N. Engl. J. Med., June 15, 1995; 332(24): 1618 - 1630. [Full Text] [PDF]